Related Experiment Video

Updated: Sep 23, 2025

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.5K

Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance

Aiping Zhang1,2, Kai Miao1,2,3, Heng Sun1,2,3

  • 1Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR, China.

International Journal of Biological Sciences
|May 11, 2022
PubMed

Insights

Tumor heterogeneity, driven by genomic mutations, fuels cancer drug resistance by altering the tumor microenvironment (TME). Understanding these mechanisms is crucial for improving cancer treatment outcomes and patient prognosis.

Area of Science:

  • Oncology
  • Cancer Biology
  • Genomics

Background:

  • Tumor heterogeneity is a key characteristic of cancer, significantly contributing to therapeutic failure.
  • It drives drug resistance by affecting therapeutic targets and modifying the tumor microenvironment (TME).
  • Tumor heterogeneity evolves dynamically, leading to continuous TME reprogramming.

Purpose of the Study:

  • To review the role of genomic mutations in driving tumor heterogeneity.
  • To explore how tumor heterogeneity reprograms the TME and influences drug resistance.
  • To highlight the impact of tumor heterogeneity on patient prognosis.

Main Methods:

  • Review of current literature on tumor heterogeneity and cancer drug resistance.
  • Analysis of molecular profiling technologies and precision oncology platforms.
  • Focus on genomic mutations and their impact on the TME.

Main Results:

  • Genomic mutations are a primary driver of tumor heterogeneity.
  • Tumor heterogeneity significantly impacts drug resistance through direct target modulation and TME reprogramming.
  • The evolving nature of tumor heterogeneity poses a continuous challenge to effective cancer therapy.

Conclusions:

  • Tumor heterogeneity is a critical factor in cancer drug resistance and therapeutic outcomes.
  • Understanding the interplay between genomic mutations, tumor heterogeneity, and the TME is essential for developing novel cancer treatments.
  • Targeting tumor heterogeneity and its effects on the TME may improve patient prognosis in oncology.
Keywords:
drug resistancetumor heterogeneitytumor microenvironment

More Related Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.1K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

18.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K